All In MedTech

PMA device

Deflux Injectable Gel

Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

9

PMA pathway

Device trials

4

Naming "Deflux"

MAUDE reports

197

Brand "Deflux", since 2015

PubMed studies

229

Mentioning "Deflux"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Deflux Injectable Gel

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 6 of 9 decisions filed under this name.

3 more FDA decisions with a free account

Older decisions: P000029-S017, P000029-S012, P000029

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.

Clinical trials

Device studies on ClinicalTrials.gov that name "Deflux", any status and sponsor, newest update first.

Open in Trial Radar
  • Trial of NASHA Dx Urethral Bulking SystemPivotal-lookingNot yet recruiting

    Palette Life Sciences, Inc.Not on our public-company list

    NCT07850804 · 314 participants (planned) · Start Sep 2026 · Primary completion Sep 2027

    Device: NASHA Dx; Bulkamid · For: Urinary Incontinence; Urinary Incontinence (UI); Urinary Incontinence , Stress and 4 more

    Sites: Tustin, California; Lincoln, Nebraska; Charlotte, North Carolina · 5 sites in all

  • Galderma R&DNot on our public-company list

    NCT01110681 · 115 participants · Start Nov 2007 · Primary completion Nov 2009

    Device: Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) · For: Fecal Incontinence

    Sites: Vancouver, Canada; HUS, Finland; Nantes, France · 15 sites in all

  • South Shore HospitalAcademic, hospital or other

    NCT00706329 · 25 participants · Start Apr 2008 · Primary completion Mar 2009

    Device: Deflux · For: Umbilical Hernia

    Sites: South Weymouth, Massachusetts

1 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Deflux", and for the whole product code for context.

This brand

197 reports: 126 malfunction, 70 injury, 1 death

Whole product code LNM

544 reports: 170 malfunction, 369 injury, 2 death

Newest reports for this brand

2 more reports with a free account

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "Deflux"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code LNM.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.